ATE145241T1 - POLYPEPTIDE CAPABLE OF INTERACTING WITH THROMBIN - Google Patents

POLYPEPTIDE CAPABLE OF INTERACTING WITH THROMBIN

Info

Publication number
ATE145241T1
ATE145241T1 AT91202009T AT91202009T ATE145241T1 AT E145241 T1 ATE145241 T1 AT E145241T1 AT 91202009 T AT91202009 T AT 91202009T AT 91202009 T AT91202009 T AT 91202009T AT E145241 T1 ATE145241 T1 AT E145241T1
Authority
AT
Austria
Prior art keywords
thrombin
gla
amino acid
polypeptide
glu
Prior art date
Application number
AT91202009T
Other languages
German (de)
Inventor
Michitaka Zushi
Komakazu Gomi
Shuji Yamamoto
Koji Suzuki
Akio Matsuda
Original Assignee
Asahi Chemical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Ind filed Critical Asahi Chemical Ind
Application granted granted Critical
Publication of ATE145241T1 publication Critical patent/ATE145241T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/7455Thrombomodulin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Disclosed is a substantially pure polypeptide having a specific amino acid sequence containing (a) an amino acid residue selected from the group consisting of Asp, Glu and Gla wherein Gla represents a gamma -carboxyglutamic acid residue or (b) a peptide or polypeptide residue consisting of at least two amino acid residues selected from Asp, Glu and Gla, wherein the above-mentioned at least two amino acid residues are all the same or combinations of the Asp, Glu and Gla. The polypeptide is capable of interacting with thrombin to form a binding therebetween, thereby exhibiting an activity to inhibit the blood coagulation and platelet aggregation by thrombin and/or an activity to promote the thrombin-catalyzed activation of protein C. This novel polypeptide has a low molecular weight so that it is suitable for oral or nasal administration.
AT91202009T 1990-08-03 1991-08-05 POLYPEPTIDE CAPABLE OF INTERACTING WITH THROMBIN ATE145241T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20497890 1990-08-03

Publications (1)

Publication Number Publication Date
ATE145241T1 true ATE145241T1 (en) 1996-11-15

Family

ID=16499445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91202009T ATE145241T1 (en) 1990-08-03 1991-08-05 POLYPEPTIDE CAPABLE OF INTERACTING WITH THROMBIN

Country Status (9)

Country Link
US (1) US5574007A (en)
EP (1) EP0474273B1 (en)
KR (1) KR930008093B1 (en)
AT (1) ATE145241T1 (en)
AU (1) AU632958B2 (en)
CA (1) CA2048425C (en)
DE (1) DE69123106T2 (en)
ES (1) ES2093674T3 (en)
HK (1) HK1000968A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
JP2001522249A (en) * 1997-06-05 2001-11-13 アボツト・ラボラトリーズ Reagents and methods useful for detecting urinary tract disorders
WO2003033515A1 (en) * 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
EP1475098B1 (en) * 2002-01-18 2015-08-05 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
US6706068B2 (en) 2002-04-23 2004-03-16 Bret A. Ferree Artificial disc replacements with natural kinematics
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
AU2003225255B2 (en) * 2002-05-01 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Novel tissue factor targeted antibodies as anticoagulants
BRPI0720158A2 (en) * 2006-10-06 2014-05-20 Asahi Kasei Pharma Corp DISSEMINATED INTRAVASCULAR COAGULATION THERAPY AND / OR IMPROVEMENT AGENTS, TO REDUCE THE PROBABILITY OF DEATH IN PATIENTS SUFFERING FROM THE SAME, METHODS FOR SELECTING PATIENTS, AND TO TREAT AND / OR IMPROVE INTRAVASCULAR COAGULATION
TW201431872A (en) 2007-03-23 2014-08-16 Asahi Kasei Pharma Corp Method for producing soluble thrombomodulin of high purity
JP2011178687A (en) * 2010-02-26 2011-09-15 Kochi Univ Preventive and/or therapeutic agent for pain caused by hematopoietic cell transplantation
AU2011246021B2 (en) 2010-04-30 2014-03-13 Asahi Kasei Pharma Corporation High-purity soluble thrombomodulin and method for producing same
US9592275B2 (en) 2011-11-15 2017-03-14 Asahi Kasei Pharma Corporation Medicament for therapeutic treatment and/or improvement of sepsis
CN112608965B (en) * 2021-01-15 2022-08-05 华东理工大学 Culture medium for producing bleomycin E by using deep sea streptomycete and preparation method thereof
CN113429459B (en) * 2021-06-16 2022-07-26 昆明医科大学第一附属医院 Anti-platelet polypeptide, pharmaceutical composition thereof and application thereof
WO2023172783A2 (en) * 2022-01-07 2023-09-14 The Government Of The United States, As Represented By The Secretary Of The Army Hemostatic composition containing recombinant human clotting factors, and method of producing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816495A1 (en) * 1987-01-08 1998-01-07 Asahi Kasei Kogyo Kabushiki Kaisha DNA coding for a peptide promoting the activation of protein C by thrombin and dprocess for producing the same
DK299087D0 (en) * 1987-06-12 1987-06-12 Novo Industri As PROTEINS AND DERIVATIVES THEREOF
AU6403590A (en) * 1989-09-25 1991-04-18 Asahi Kasei Kogyo Kabushiki Kaisha Isolated, physiologically active human thrombomodulin polypeptide

Also Published As

Publication number Publication date
HK1000968A1 (en) 1998-05-15
EP0474273B1 (en) 1996-11-13
EP0474273A3 (en) 1992-04-08
EP0474273A2 (en) 1992-03-11
DE69123106T2 (en) 1997-04-10
DE69123106D1 (en) 1996-12-19
AU632958B2 (en) 1993-01-14
ES2093674T3 (en) 1997-01-01
CA2048425C (en) 1998-04-21
CA2048425A1 (en) 1992-02-04
KR920004419A (en) 1992-03-27
US5574007A (en) 1996-11-12
KR930008093B1 (en) 1993-08-25

Similar Documents

Publication Publication Date Title
DE69123106D1 (en) Polypeptide capable of interacting with thrombin
DK473888D0 (en) PEPTID, PROCEDURES FOR PREPARING THEREOF AND MEDICINAL PRODUCT CONTAINING PEPTID
DE3650645D1 (en) Antigenic proteins and vaccines containing them to prevent coccidiosis
DE3587512D1 (en) SHELL-ANTIGED FROM THE HUMAN IMMUNODEFICIENCY VIRUS AND THEIR USE.
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
FI953658A (en) Stable bactericidal / permeation enhancing protein products and pharmaceutical compositions containing them
EP0378641A4 (en) Novel antimicrobial peptide, compositions containing same and uses thereof
EP0458959A4 (en) Novel platelet-derived growth factor b chain analogs and method for homogeneous production thereof
ATE84798T1 (en) TRANSFORMATIONAL GROWTH FACTOR BETA.
NZ228710A (en) Modified "echistatin" and anti-clotting pharmaceutical composition
EP0257312A3 (en) A new cartilage-derived leukocyte elastase-inhibitor
HUT50195A (en) New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions
DK370489D0 (en) RECOMBINANT HUMANT INTERLEUKIN-2, ITS MANUFACTURING AND USE AS A MEDICINE
SE8801723D0 (en) FIBRONECTIN BINDING PROTEIN AS WELL AS IT'S PREPARATION
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
ATE108833T1 (en) ANTIBODIES AGAINST FIBRIN, IMMUNOGENIC PEPTIDES FOR THE PRODUCTION OF THESE ANTIBODIES, METHODS FOR THE DETERMINATION OF FIBRIN AND PHARMACEUTICAL PREPARATIONS BASED ON THESE ANTIBODIES.
EP0723016A3 (en) Activating factor of leukocytes
ATE241698T1 (en) HST-2 MUTEIN, DNA CODING IT AND PRODUCTION
DE68917520D1 (en) Methods and systems for producing HIV antigens.
ATE108207T1 (en) POLYPEPTIDES AND DNA CODING THEREFOR.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee